Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

Economic Recovery Debate Heats Up: 4 Sectors Holding Ground

by Urmimala Biswas

Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.

Zacks Equity Research

AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe

by Zacks Equity Research

AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.

Sweta Jaiswal, FRM headshot

Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

by Sweta Jaiswal, FRM

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $60.20 in the latest trading session, marking a +0.22% move from the prior day.

Zacks Equity Research

J&J to Begin Human Study on Coronavirus Vaccine in July

by Zacks Equity Research

J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.

Sanghamitra Saha headshot

Fed Sparks Economic Concerns: Winning Investment Strategies

by Sanghamitra Saha

The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.

Ritujay Ghosh headshot

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

by Ritujay Ghosh

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

Zacks Equity Research

Moderna (MRNA) Up 9.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Novavax Clinches $60M Defense Contract for Coronavirus Vaccine

by Zacks Equity Research

Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.

Zacks Equity Research

AstraZeneca to Ensure Equal Access to Coronavirus Vaccine

by Zacks Equity Research

AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.